Phase 3CompletedINTERVENTIONAL
A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Dulaglutide in Participants With T2DM
ClinicalTrials.gov · NCT05680129 · Registry updated: 2025-05-08
- Condition / research focus
- T2DM; Type 2 Diabetes Mellitus
- Sponsor
- Hangzhou Sciwind Biosciences Co., Ltd.
- Countries with listed sites
- China
- Registry dates and results
- Start: 2023-01-10. Completion: 2024-10-12 (may be estimated). No results posted in this registry response.
Products and interventions (4)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
- Ecnoglutide high dosage (drug) — also listed as: XW003
- Ecnoglutide low dosage (drug) — also listed as: XW003
- Dulaglutide (drug)
- Metformin (drug)
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
- Shanghai, Shanghai Municipality, China